Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.65 EUR | -0.52% | +16.92% | +123.55% |
07-17 | Mind Medicine Says New Patent Secured for Investigational Anxiety Disorder Treatment MM120 | MT |
07-17 | Mind Medicine Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet | CI |
Evolution of the average Target Price on Mind Medicine (MindMed) Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Mind Medicine (MindMed) Inc.
Baird | |
Oppenheimer | |
Leerink Partners | |
RBC Capital Markets | |
Roth MKM | |
EF Hutton | |
HC Wainwright | |
Cantor Fitzgerald | |
Roth Capital Partners |
EPS Revisions
- Stock Market
- Equities
- MNMD Stock
- MMQ Stock
- Consensus Mind Medicine (MindMed) Inc.